Trial Profile

A real-life study to assess efficacy and safety of ponatinib in real life clinical practice in Chronic myeloid leukaemia patients treated for less than 6 months

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Dec 2022 Last interim results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" in Patients with TKI-Resistant or Intolerant CML presented at the 64th American Society of Hematology Annual Meeting and Exposition
22 Jul 2020 New trial record
21 Jun 2020 Results (n=75; as of 14 Feb 2020) of intermediate analysis of a TKI-resistant cohort of TOPASE study presented at the 25th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com